CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) (USD $) In Millions, except Per Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2013		Apr. 01, 2012
Revenues	$ 13,500		$ 14,885
Costs and expenses:
Cost of sales	2,652	[1]	2,745	[1]
Selling, informational and administrative expenses	3,585	[1]	3,968	[1]
Research and development expenses	1,800	[1]	2,062	[1]
Amortization of intangible assets	1,234		1,420
Restructuring charges and certain acquisition-related costs	138	[2]	597	[2]
Other deductions-net	170		1,658
Income from continuing operations before provision for taxes on income	3,921	[3]	2,435	[3]
Provision for taxes on income	1,160		711
Income from continuing operations	2,761		1,724
Discontinued operations-net of tax	4		79
Net income before allocation to noncontrolling interests	2,765		1,803
Less: Net income attributable to noncontrolling interests	15		9
Net income attributable to Pfizer Inc.	$ 2,750		$ 1,794
Earnings per common share-basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	$ 0.38		$ 0.23
Discontinued operations-net of tax (in dollars per share)	$ 0.00		$ 0.01
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	$ 0.38		$ 0.24
Earnings per common share-diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	$ 0.38		$ 0.23
Discontinued operations-net of tax (in dollars per share)	$ 0.00		$ 0.01
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	$ 0.38		$ 0.24
Weighted-average shares-Basic	7,187		7,537
Weighted-average shares-Diluted	7,269		7,598
Cash dividends paid per common share (in dollars per share)	$ 0.24		$ 0.22

[1] Excludes amortization of intangible assets, except as disclosed in Note 9B. Goodwill and Other Intangible Assets: Other Intangible Assets.

[2] From the beginning of our cost-reduction/productivity initiatives in 2005 through March 31, 2013, Employee termination costs represent the expected reduction of the workforce by approximately 62,000 employees, mainly in manufacturing and sales and research, of which approximately 54,000 employees have been terminated as of March 31, 2013. For the three months ended March 31, 2013, the credit to employee terminations reflects a change in estimate related to the number of employees to be terminated and the expected total cost of planned terminations.The restructuring charges for the three months ended March 31, 2013 are associated with the following:•Primary Care operating segment ($5 million income), Specialty Care and Oncology operating segment ($6 million), Established Products and Emerging Markets operating segment ($11 million), other operating segments ($2 million), research and development operations ($2 million), manufacturing operations ($4 million) and Corporate ($79 million).The restructuring charges for the three months ended April 1, 2012 are associated with the following:•Primary Care operating segment ($3 million), Specialty Care and Oncology operating segment ($3 million), Established Products and Emerging Markets operating segment ($3 million), other operating segments ($6 million), research and development operations ($12 million), manufacturing operations ($152 million) and Corporate ($318 million).

[3] Income from continuing operations before provision for taxes on income.